BACKGROUND AND OBJECTIVES: An eight-member group consisting of Canadian infectious disease and immunology specialists and a family physician with significant experience in HIV management was convened to update existing recommendations, specifically intended for use by Canadian HIV-treating physicians, on the appropriate use of enfuvirtide in HIV/AIDS patients with resistance to other antiretroviral drugs.METHODS: Evidence from the literature and expert opinions of the group members formed the basis of the guidelines. Comments on the draft guidelines were obtained from other physicians across Canada with HIV expertise. The final guidelines represent the group's consensus agreement.RESULTS AND CONCLUSIONS: The recommendations were developed t...
Combination antiretroviral therapy against the hu-man immunodeficiency virus (HIV) has been re-marka...
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major ...
For full HIV virological suppression, three fully active antiretroviral agents are required. New dru...
BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV ma...
BACKGROUND: The management of HIV-infected patients with cytomegalovirus (CMV) disease has changed s...
BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with...
BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge i...
Enfuvirtide was the first agent to re-ceive Food and Drug Administration approval in a novel class o...
Objectives: To describe patterns of knowledge regarding the therapeutic management of HIV-disease a...
Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (...
It has been 120 years since the first case of AIDS was identified. There has been a significant and ...
Managing human immunodeficiency virus (HIV) disease and the acquired immunodeficiency syn-drome (AID...
Recent data from clinical trials investigating the efficacy of enfuvirtide, a fusion inhibitor, in t...
care and retention in that care are essential to the provision of effective antiretroviral therapy (...
Background The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management ...
Combination antiretroviral therapy against the hu-man immunodeficiency virus (HIV) has been re-marka...
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major ...
For full HIV virological suppression, three fully active antiretroviral agents are required. New dru...
BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV ma...
BACKGROUND: The management of HIV-infected patients with cytomegalovirus (CMV) disease has changed s...
BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with...
BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge i...
Enfuvirtide was the first agent to re-ceive Food and Drug Administration approval in a novel class o...
Objectives: To describe patterns of knowledge regarding the therapeutic management of HIV-disease a...
Evidence-based guidelines for the management of persons infected with human immunodeficiency virus (...
It has been 120 years since the first case of AIDS was identified. There has been a significant and ...
Managing human immunodeficiency virus (HIV) disease and the acquired immunodeficiency syn-drome (AID...
Recent data from clinical trials investigating the efficacy of enfuvirtide, a fusion inhibitor, in t...
care and retention in that care are essential to the provision of effective antiretroviral therapy (...
Background The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management ...
Combination antiretroviral therapy against the hu-man immunodeficiency virus (HIV) has been re-marka...
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major ...
For full HIV virological suppression, three fully active antiretroviral agents are required. New dru...